This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Pyruvate dehydrogenase kinase
From Proteopedia
| Line 41: | Line 41: | ||
**[[2zdx]], [[2zdy]] – hPDK4 (mutant) + inhibitor | **[[2zdx]], [[2zdy]] – hPDK4 (mutant) + inhibitor | ||
}} | }} | ||
| + | == References == | ||
| + | <references/> | ||
[[Category: Topic Page]] | [[Category: Topic Page]] | ||
Revision as of 10:05, 2 August 2016
Contents |
Function
Pyruvate dehydrogenase kinase (PDK) is part of the pyruvate dehydrogenase complex. This complex is located in the mitochondria and converts pyruvate to acetyl-CoA as part of the citric acid cycle. PDK phosphphorylates serine residues on pyruvate dehydrogenase using ATP. There are 4 isozymes of PDK. The isozymes differ in length, activity and phosphorylation sites[1].
Relevance
Inhibition of PDK decreases the damage caused by heart ischemia and are used in diabetes and cancer patients[2][3].
3D structures of pyruvate dehydrogenase kinase
Updated on 02-August-2016
References
- ↑ Korotchkina LG, Patel MS. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J Biol Chem. 2001 Oct 5;276(40):37223-9. Epub 2001 Aug 2. PMID:11486000 doi:10.1074/jbc.M103069200
- ↑ Roche TE, Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol Life Sci. 2007 Apr;64(7-8):830-49. PMID:17310282 doi:10.1007/s00018-007-6380-z
- ↑ Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol. 2013 Mar 7;3:38. doi: 10.3389/fonc.2013.00038. eCollection 2013. PMID:23471124 doi:http://dx.doi.org/10.3389/fonc.2013.00038
